Abstract
The aim of this study was to evaluate prognostic effect of the angiogenesis regulators VEGF-R1, VEGF-R2 and VEGF-A for recurrent disease and disease-free survival (DFS), and their relation to the apoptosis regulator p53, in 131 patients with FIGO-stages I-II with epithelial ovarian cancer. For the detection of positivity of the markers the techniques of tissue microarrays and immunohistochemistry (IHC) were used. In tumors the frequency of positive staining for VEGF-R1 was 19%, for VEGF-R2 and VEGF-A, it was 77 and 70%, respectively. Positivity for p53 was detected in 25% of tumors. The total number of recurrences in the complete series was 34 out of 131 (26%) and 5-year disease-free survival (DFS) was 68%. Positive staining for VEGF-A (P=0.030), VEGF-R2 (P=0.011) and p53 (P=0.015) was found more frequently in type II tumors than in type I tumors. Patients with VEGF-R1 negative tumors had worse (P=0.021) DFS compared to patients with VEGF-R1 positive tumors. In two multivariate Cox analyzes with DFS as endpoint, FIGO-stage (HR=3.8), VEGF-R2 status (HR=0.4) and p53 status (HR=2.3), all were significant and independent prognostic factors. When the variables VEGF-R2 and p53 were replaced with the new variable VEGF-R2+p53-/other th...Continue Reading
References
Jul 1, 1997·Cancer·P J PaleyS Ramakrishnan
Jul 14, 1998·Nature Medicine·J KononenO P Kallioniemi
Jul 20, 2000·British Journal of Cancer·G H ShenY Sugisaki
Nov 2, 2001·The American Journal of Surgical Pathology·T SeidalH Battifora
Sep 16, 2004·Cancer·Naoyo NishidaMasamichi Kojiro
Dec 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J Hicklin, Lee M Ellis
May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael J GoodheartRichard E Buller
Sep 26, 2006·Cancer Letters·Chandrashekhar D KamatMichael A Ihnat
May 8, 2007·Gynecologic Oncology·Angeles Alvarez SecordUNKNOWN Gynecologic Oncology Group study
Dec 5, 2008·PLoS Medicine·Martin KöbelDavid Huntsman
Jan 8, 2009·Journal of Clinical Pathology·K EngelsS Loibl
Jun 11, 2009·British Journal of Cancer·P de GraeffG H de Bock
Mar 3, 2010·Laboratory Investigation; a Journal of Technical Methods and Pathology·Sirin A I AdhamBrenda L Coomber
Apr 10, 2010·Journal of Gynecologic Oncology·Robert A Burger
May 6, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Jonathan A LedermannUNKNOWN Gynecologic Cancer InterGroup
Dec 30, 2011·The New England Journal of Medicine·Timothy J PerrenUNKNOWN ICON7 Investigators
Dec 5, 2012·Cold Spring Harbor Perspectives in Medicine·Mark W KieranYoon-Jae Cho
Mar 2, 2013·Cell Death and Differentiation·M Farhang GhahremaniJ J Haigh
Jan 1, 2010·Cancers·Cécile Le PageAnne-Marie Mes-Masson
Jun 24, 2014·Gynecologic Oncology·Nadeem Abu-RustumAnil K Sood
Oct 16, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chad TangDavid S Hong
Jan 20, 2015·Gynecologic Oncology·Juanni LiXiaoying Wu
Apr 4, 2015·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Xiaolian ZhangAiping Qin
Citations
May 29, 2018·Integrative Cancer Therapies·Cheng ZhangYibin Feng
Feb 6, 2020·The Journal of Obstetrics and Gynaecology Research·Noriko SatoTadashi Kimura
Aug 2, 2018·International Journal of Oncology·Ingiridur SkirnisdottirTomas Seidal
Aug 24, 2019·Aging·Na LiXianquan Zhan
Jun 14, 2017·PloS One·Kathrine BjersandIngiridur Skirnisdottir
Oct 11, 2017·PloS One·Beata KotowiczMaria Kowalska
Jan 10, 2017·Molecular BioSystems·Zichuang YanYan Xu
Nov 9, 2020·The Pharmacogenomics Journal·Valéria TavaresRui Medeiros
Nov 18, 2018·Human Pathology·Amilcar BarretaSophie Derchain
Jul 20, 2021·IScience·Allison L HuntThomas P Conrads